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Key Points 27 
Question: Do polygenic liabilities for major depression (MD), bipolar disorder (BD) and schizophrenia 28 
(SZ) predict depression in the general population? 29 
Findings: In this case-cohort study including 34,573 individuals representative of the Danish 30 
population, each 1 standard deviation increase in polygenic risk for MD was associated with a 30% 31 
increase in hazard of depression. Polygenic liabilities for SZ and BD were also associated with 32 
increased hazard of depression, but to a lesser extent.  33 
Meaning: Polygenic risk scores trained in samples of prevalent MD cases can predict first depression 34 
in the general population.  35 
  36 
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Tweet 37 
New study from iPSYCH shows risk for depression diagnosis in the general population increases by 38 
30% per standard deviation increase in polygenic risk  39 
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Abstract 40 
Importance: Although the usefulness of polygenic risk scores as a measure of genetic liability for 41 
major depression (MD) has been established, their capacity to predict who will develop depression in 42 
the general population remains relatively unexplored. 43 
Objective: To evaluate whether polygenic risk scores for MD, bipolar disorder (BD) and schizophrenia 44 
(SZ) predict depression in the general population, and explore whether these polygenic liabilities are 45 
associated with heterogeneity in age at onset and severity at initial depression diagnosis. 46 
Design, Setting and Participants: Participants were drawn from the Danish iPSYCH2012 case-cohort 47 
study: a representative sample drawn from the population of Denmark born between May 1, 1981 and 48 
December 31, 2005. Hazard of depression was estimated using Cox regressions modified to 49 
accommodate the case-cohort design. Case-only analyses were conducted using linear and multinomial 50 
regressions. Data analysis was conducted from February 2017 to June 2018.  51 
Exposure: Polygenic risk scores for MD, BD and SZ trained using the most recent GWAS results from 52 
the PGC.  53 
Main Outcome and Measures: First depressive episode (ICD-10 code F32) treated in specialty care. 54 
Severity at initial diagnosis was measured using ICD-10 code severity specifications (mild, moderate, 55 
severe without psychosis, severe with psychosis) and treatment setting (inpatient, outpatient, 56 
emergency). 57 
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Results: The sample was 51% male and included 34,573 individuals (14,799 depression cases) aged 58 
10-31 years at censoring. Each standard deviation increase in polygenic liability for MD, BD and SZ 59 
was associated with 30% (HR=1.30, 95% CI [1.27, 1.33]), 5% (1.05, [1.02, 1.07]) and 12% (1.12, 60 
[1.09, 1.15]) increases in hazard of depression, respectively. Among cases, higher polygenic liability 61 
for BP was associated with earlier depression onset (p=.002).  62 
Conclusions: Polygenic liability for MD predicts first depression in the general population, supporting 63 
the idea that these scores tap into an underlying liability for developing the disorder. The fact that PRS-64 
BD and PRS-SZ also predicted depression is consistent with prior evidence that these disorders share a 65 
degree of common genetic overlap. Variation in polygenic liability may contribute slightly to 66 
heterogeneity in clinical presentation, but these effects appear minimal. 67 
  68 
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Introduction 69 
Genes play a moderate role in the etiology of depression, with twin-based heritability estimates ranging 70 
from 30-40%
1
 and SNP-based heritability estimates ranging from 9-29%.
2-4
 Large empirical studies of 71 
the genetic architecture of depression indicate that it is polygenic, meaning that the contribution of 72 
genetic factors is attributable to small effects of hundreds or thousands of genetic variants spread across 73 
the genome.
3,5
 74 
To date, multiple studies have shown small but statistically significant associations between polygenic 75 
risk scores (PRS) – a weighted sum of the number of variants associated with the disorder in a different 76 
dataset – and depression.6-9 However, these studies focused on prevalent depression, which is more 77 
likely than incident depression to be recurrent or chronic.
10,11
 Since the genome-wide association study 78 
(GWAS) data underpinning the PRSs are largely based upon prevalent cases, this could suggest that 79 
part of the genetic architecture discovered in GWAS studies is linked to chronicity or recurrence rather 80 
than the risk of developing the disorder. Therefore, while the usefulness of polygenic risk scores as a 81 
measure of genetic liability for depression has been established, their capacity to predict who will 82 
develop depression in the general population remains relatively unexplored. 83 
In addition to heterogeneity in chronicity and recurrence, depression is also characterized by substantial 84 
variation in characteristics such as age at onset and symptom severity. Research suggests that this 85 
variation may be due at least partially to differences in genetic liability. Family studies demonstrate that 86 
individuals with a parental history of major depression (MD) are at increased risk for onset of 87 
depression at earlier ages, 
12-15
 and recent results from the Psychiatric Genomics Consortium (PGC) 88 
showed that polygenic risk for depression had a stronger effect on the odds of early vs. late onset 89 
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depression.
4
 Research also suggests that individuals with severe MD may have a higher genetic burden 90 
than individuals with milder symptoms: A recent GWAS in Han Chinese women found an increased 91 
genetic signal among individuals with melancholia,
16
 and the PGC reported higher PRSs among severe 92 
vs. moderate depression cases.
4
 93 
Our primary aim in this study was to evaluate the extent to which polygenic liability is associated with 94 
risk for first depressive episode in the general population. As a secondary aim, we examined whether 95 
polygenic liability is associate with severity and age at onset at first depression diagnosis. Because 96 
prior evidence suggests a possible shared genetic etiology between depression and other psychiatric 97 
disorders,
2,4,17
 we also examined the extent to which PRSs for bipolar disorder (BD) and schizophrenia 98 
(SZ) effect the risk for developing depression in the general population. To accomplish these aims, we 99 
used data from the iPSYCH2012 sample, a unique and powerful dataset that links genetic information 100 
with longitudinal phenotype data from Danish national registers. 101 
Methods 102 
Study design  103 
For a detailed description of the iPSYCH2012 sample, see Pedersen et al.
18
 Briefly, The iPSYCH2012 104 
sample has a case-cohort design
19, which consists of two parts: a random sample (i.e. ‘subcohort’) of 105 
individuals drawn from a specified base population (i.e. ‘full cohort’) and all additional cases from the 106 
full cohort that were not selected as part of the subcohort. Like a traditional cohort study, a case-cohort 107 
study can obtain accurate estimates of hazard and risk using traditional survival analysis, provided the 108 
analyses are modified to address issues related to point and variance estimation caused by 109 
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oversampling cases.
19-22
 For a more detailed description of the case-cohort design see the Supplemental 110 
Methods.  111 
In the iPSYCH2012 sample, the subcohort consists of a random sample of 30,000 individuals drawn 112 
from the full cohort of all singletons born in Denmark between May 1, 1981 and December 31, 2005 113 
who were alive and living in Denmark on their first birthday and had known mothers (N=1,472,762).
18
 114 
The full cohort was identified using information from the Danish Civil Registration system (DCRS).
23
 115 
The iPSYCH2012 study includes all individuals from the full cohort who were diagnosed with 116 
depression in a psychiatric hospital in Denmark between 1991 and 2012 at the age of 10 or older. 117 
Information on psychiatric diagnoses was obtained from the Danish Central Psychiatric Research 118 
Register (DCPRR).
24
 Diagnoses are based on the ICD-10 Classification of Mental and Behavioural 119 
Disorders: Diagnostic Criteria for Research.
25
  120 
Sample selection 121 
We began by selecting all members of the subcohort and all cases outside the subcohort whose first 122 
depression diagnosis in the DCPRR was F32 – ‘depressive episode’. We focused exclusively on 123 
individuals with Danish-born parents in order to reduce heterogeneity in genetic ancestry. The sample 124 
was further restricted to individuals who were successfully genotyped as part of the iPSYCH2012 125 
sample, passed quality control (QC) measures, and were alive, living in Denmark and at least 10 years 126 
old by the end of follow up (December 31, 2012). Seventy-six individuals were removed from the 127 
subcohort because their first depression diagnosis in the register was F33 – ‘recurrent depressive 128 
disorder’, and we were thus unable to identify their first depressive episode. The final sample included 129 
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34,573 individuals: 20,082 members of the subcohort (of whom 308 were depression cases) and 14,491 130 
depression cases outside the subcohort (Supplemental Figure S1).  131 
This study was approved by the Danish Data Protection Agency. By Danish law, register-based studies 132 
do not require informed consent.  133 
Genotyping 134 
For a more detailed description of genotyping and quality control (QC) in the iPSYCH2012 cohort, see 135 
Pedersen et al.
18
 Briefly, DNA was collected from blood spots drawn as part of routine clinical testing 136 
at birth and stored at The Danish Neonatal Screening Biobank.
26
 Blood spots were located for 80,422 137 
of the 86,189 members of the original iPSYCH2012 sample (93.3%). Genotyping was performed at the 138 
Broad Institute of Harvard and MIT (Cambridge, MA, USA) using the Infinium PsychChip v1.0 array 139 
(Illumina CA, San Diego, USA) according to the manufacturer’s protocols.27 QC and imputation (using 140 
1000 genomes as reference panel) were conducted using the Ricopili pipeline. As the iPSYCH2012 141 
sample is population-based, individuals from the same nuclear family unit were neither purposely 142 
sampled nor purposely removed.  143 
Measures 144 
Age at onset (AAO) was operationalized as the individual’s age in years at first F32 diagnosis in the 145 
DCPRR. Information on severity was obtained from the ICD-10 diagnostic code: Mild (F32.0); 146 
Moderate (F32.1); Severe without psychotic features (F32.2); Severe with psychotic features (F32.3). 147 
We also examined differences in treatment setting (inpatient, emergency, outpatient) as cases treated in 148 
inpatient or emergency settings are likely more severe than cases treated in an outpatient setting. 149 
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Polygenic risk scores. PRSs were calculated using a standard approach,
28
 in which an LD-pruned 150 
discovery dataset is used to identify autosomal SNPs associated with the outcome at varying p-value 151 
thresholds (p(t)), and then a score is calculated for each individual in a target dataset corresponding to 152 
the weighted sum of each subject’s allelic burden at that threshold. Polygenic risk scores for MD and 153 
SZ were created using the Ricopili process with the most recently published GWAS results from the 154 
PGC (not including iPSYCH2012) as discovery datasets.
4,29
 The discovery dataset for BD was 155 
comprised of leave-one-out summary statistics provided in advance of the latest GWAS publication 156 
from the BP Working Group of the PGC.
30
 SNPs from the discovery datasets were filtered at INFO > 157 
0.9 and MAF > .05, and the broad MHC-region (chr6: 25-35MB) was removed. Additionally SNPs 158 
were only included in the scores if they were reliably genotyped or imputed across all 23 waves of the 159 
iPSYCH2012 sample, at INFO > 0.6 and MAF > .01. Ten PRSs were calculated for each disorder (30 160 
total) at the following p-value thresholds: p < .00000005; 0.000001; 0.0001; 0.001; 0.01; 0.05; 0.1; 0.2; 161 
0.5; 1.0 (See Supplemental Table S1 for SNP numbers).
31
 PRSs were standardized using the means and 162 
standard deviations from the distributions in subcohort members with Danish ancestry (N=22,182). As 163 
the iPSYCH2012 subcohort is a simple random sample drawn from the base population, the 164 
distribution of PRSs in the subcohort approximates the distribution in the Danish-born population.  165 
Statistical analysis 166 
Hazard of depression was estimated using Cox regressions with days since 10
th
 birthday as the 167 
timescale. Individuals entered the analysis on their 10
th
 birthday and were censored on the date of their 168 
first F32 diagnosis in the DCPRR, death, emigration, or December 31, 2012, whichever came first. The 169 
oldest participants were 31 years at diagnosis or censoring. We used robust standard errors and Barlow 170 
weighting to account for oversampling of cases
22,32
. All models were adjusted for sex and the top four 171 
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ancestral principal components. Additionally, all models were stratified by birth year (1981-2002) to 172 
control for secular trends in diagnostic practices and because fewer bloodspots were retrievable among 173 
individuals born in earlier years.  174 
To examine whether polygenic liability has a stronger association with early-onset depression, we 175 
conducted separate Cox regressions, in each analysis considering as outcome only depression with 176 
onset in a specific age range. Thus, we estimated separately the association of PRSs with hazard of 177 
depression with diagnosis at ages 10-15, 16-20, 21-25 and 26-31, respectively. Likewise, we conducted 178 
separate Cox regressions considering respectively mild, moderate, severe without psychotic features, 179 
severe with psychotic features, inpatient, emergency and outpatient treatment setting at first depression 180 
as outcome in each of the analyses. We also examined the associations between PRSs, AAO and 181 
severity among cases only. Associations with age at onset in days were estimated using linear 182 
regressions. Associations with severity measures were estimated using multinomial logistic regressions. 183 
All case-only regressions were adjusted for the first 4 PCs, sex and birth year. Statistical significance 184 
was assessed at the bonferroni-corrected alpha level p < .017. Analyses were conducted in SAS 9.4 185 
(See Appendix in the Supplemental Materials for SAS code).  186 
Results 187 
Sample characteristics 188 
Table 1 shows sample characteristics. Non-cases were 49% female, which was expected given that the 189 
subcohort is a representative sample of the Danish population. MD cases were 68% female, which was 190 
also expected given that the typical female to male ratio of depression in the population is 2:1.
33
 AAO 191 
ranged from 10 to 31 years, with a mean of 19.1 years (SD = 4.1 years). Seventeen percent of the cases 192 
12 
 
were classified as mild, 45% as moderate, 9% as severe, 3% as psychotic and 25% had no ICD-10 193 
severity specification. The majority (60%) were treated in an outpatient setting.  194 
Polygenic liability and hazard of depression 195 
For all three polygenic risk scores (PRS-MD, PRS-BD and PRS-SZ), the strength of the association 196 
increased as the stringency of the p(t) threshold decreased up to p(t) < .05 (Supplemental Table S2 and 197 
Supplemental Figures S2-S7). For this reason and to maintain consistency with prior research, we 198 
present results from the p(t) < .05 thresholds throughout the remainder of the manuscript.  199 
Each standard deviation (SD) increase in PRS-MD was associated with a 30% increase in the hazard of 200 
depression (95% CI = 1.27-1.33; p < .0001). In other words, compared to an individual with average 201 
polygenic liability, an individual one SD above the population average had a 30% increased risk of 202 
depression diagnosis before age 31. The corresponding values for PRS-BD and PRS-SZ were 5% 203 
(1.02-1.07; p < .0001) and 12% (1.09-1.15; p < .0001), respectively (Table S2). Figure 1 shows the 204 
associations between PRS deciles and hazard of depression, with the bottom decile (i.e. the lowest 10% 205 
of the PRS distribution) as the reference category. Relative to individuals in the bottom decile, 206 
individuals in the top decile of PRS-MD had a hazard ratio of 2.55 (2.28-2.85; p < .0001). The 207 
corresponding values were 1.22 (1.10-1.36; p < .0001) for PRS-BD and 1.49 (1.34-1.66; p < .0001) for 208 
PRS-SZ (Supplemental Table S3). 209 
AAO 210 
As shown in Figure 2 and Table 2, the hazard of depression per SD increase in PRS-MD was slightly 211 
higher for first diagnosis between 16-20 years (1.31, 1.27-1.35) and 21-25 years (1.32, 1.27-1.38), 212 
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compared to 10-15 years (1.27, 1.22-1.33) or  26-31 years (1.24, 1.16-1.32). The effect of PRS-BD was 213 
strongest for diagnosis between ages 10-15 years (1.08, 1.04-1.12) and decreased linearly with age. 214 
PRS-SZ was also for diagnosis between 10-15 years (1.17, 1.12-1.22), but lowest for diagnosis 215 
between 21-25 years (1.08, 1.04-1.13). Case-only analyses showed small associations between higher 216 
polygenic risk scores and earlier age at onset across all scores, but only the association for PRS-BD 217 
survived correction for multiple testing (Table 3). 218 
Severity 219 
The effects of PRS-MD, PRS-BP and PRS-SZ were all strongest for psychotic depression (Figure 2, 220 
Table 2). Differences by severity were most pronounced for PRS-SZ (1.20, 1.09-1.32) and least 221 
pronounced for PRS-MD (1.33, 1.23-1.45). In the case-only analyses, none of the associations were 222 
statistically significant; however the association between higher PRS-SZ and increased odds of 223 
psychotic depression was suggestive (OR=1.10, 95% CI [1.00- 1.21]; p = .06) (Table 3).  224 
The effects of PRS-MD, PRS-BD and PRS-SZ were larger for inpatient and emergency treatment, but 225 
the differences in effect size were small (Figure 2). PRS-MD was marginally associated with increased 226 
odds of emergency treatment in the case-only analyses (OR=1.05, 95% CI [1.01- 1.09]; p = .02) (Table 227 
3). 228 
Discussion 229 
In this study, we found that polygenic risk scores trained using aggregated results from selected 230 
samples of prevalent, often recurrent depression cases contributed meaningfully to risk for first 231 
depression in the Danish general population. For each SD increase in polygenic liability, hazard of 232 
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depression increased by 30%. Relative to individuals in the bottom 10% of the polygenic liability 233 
distribution, the hazard of depression was 2.55 times higher among individuals in the top 10%. These 234 
results suggest that estimates of genetic liability ascertained using prevalent samples are tapping in to 235 
an underlying genetic predisposition for developing depression, not just a predisposition to maintain the 236 
disorder once it has been established. Polygenic liability for BD and SZ predicted depression to a lesser 237 
extent than PRS-MD, which supports the well-documented finding that these disorders share a degree 238 
of common genetic etiology. 239 
The effect of polygenic liability on age at onset in this study was much smaller than prior findings from 240 
family studies would suggest. This could reflect the fact that PRSs and family background are not 241 
entirely overlapping measures of genetic risk. Previous research suggests that some, but not all, of the 242 
effect of family history of schizophrenia is mediated by polygenic risk.
34
 If the same holds true for 243 
depression, the larger effects identified in family studies may be attributable to the portion of the family 244 
history effect not captured by a PRS, or possibly to increased vigilance for psychiatric disorders among 245 
multiplex families. It should also be noted that the oldest members of the iPSYCH2012 cohort were 246 
only 31 at the end of follow-up, around the median age of onset for depression.
35
  As a result, the entire 247 
sample could be considered ‘early onset.’ It may be that more pronounced differences exist in the 248 
effects of PRS-MD on risk for depression at different points across the lifespan, but that these 249 
differences are less apparent when comparing groups of younger individuals. 250 
We found little association between polygenic liability and greater severity at initial depression 251 
diagnosis, which is inconsistent with recent findings from the PGC
4
. In general, past studies with 252 
positive findings in this area have focused on severity measures that relate to illness course, such as 253 
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number of depressive episodes and chronicity of depressive symptoms
36-38
. It could be that polygenic 254 
liability has less of an impact on characteristics of the first depressive episode than it does on 255 
characteristics of course. 256 
It has been suggested previously that stratifying on the phenotype may be a viable method to increase 257 
statistical power for identifying genetic variants associated with depression.
39
 This method has been 258 
used with some success by the CONVERGE consortium, which identified a locus significantly 259 
associated with depression in Han Chinese women by selecting for highly severe, recurrent female 260 
cases
16
. Polygenic risk was also found to be differentially associated with subtypes in autism
31
, bipolar 261 
disorder and schizophrenia
30
. However, for depression, greater success in gene discovery was achieved 262 
by increasing sample size at the expense of a carefully defined phenotype.
4,40
 In this vein, the results of 263 
the current study indicate that the usefulness of further stratification on the phenotype for gene 264 
discovery in depression might be more limited than we may have wished. 265 
We found some evidence of genetic heterogeneity among depression cases in terms of polygenic 266 
liabilities for BD and SZ: there was a suggestive (although not significant) association between PRS-267 
SZ and depression with psychotic symptoms, which makes intuitive sense. PRS-BD was significantly 268 
associated with earlier age at MD onset in the case-only analyses, and the case-cohort analyses in 269 
separate age groups suggest that PRS-BD and PRS-SZ may be particularly elevated among individuals 270 
diagnosed with MD between the ages of 10-15. These results are consistent with past studies
41,42
 and 271 
could suggest that a person’s degree of genetic liability for BD or SZ may place them at increased risk 272 
for different clinical manifestations of depression. However, psychiatric diagnoses are often unstable 273 
over time, and both early age at onset and greater severity/psychotic symptoms are robust risk factors 274 
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for converting to BD or SZ.
43-45
 It is therefore possible that these results reflect the fact that many 275 
individuals with BD and SZ receive a depression diagnosis during the early stages of their illness.  276 
Strengths and Limitations 277 
The iPSYCH2012 sample has many strengths, including large sample size, population-based sampling 278 
and a uniform case definition. The fact that cases were identified through clinical records rather than 279 
selected specifically for research increases the relevance for clinical practice. In addition, the ancestral 280 
homogeneity of the Danish population reduces the likelihood of confounding by population 281 
stratification.  282 
It should be noted, however, that although cases in the iPSYCH2012 sample are representative of 283 
individuals who received treatment for depression in psychiatric hospitals, they do not include 284 
depression cases who are untreated or only treated by general practitioners
46,47
. To put this into 285 
perspective, currently unpublished results show that the majority (85%) of individuals treated for 286 
depression in Denmark are treated first by their primary care doctors, though this proportion was lower 287 
in younger age groups.
48
 The cases in the iPSYCH2012 sample therefore represent the severe end of 288 
the depression distribution in Denmark, which is both a strength and a limitation. Severe cases are 289 
likely enriched for genetic determinants
16
, however the results may not generalize to milder forms of 290 
depression, and they could be biased towards the null due to misclassification. Additionally, there 291 
might be too little variation in severity to assess the effect of polygenic liability on severity in this 292 
sample.  The analyses may also be subject to selection bias, if specialty-treated depression cases are 293 
more likely than untreated or primary-care treated cases to experience recurrent episodes. It is also 294 
worth noting that because we focused exclusively on first depression, we did not account for 295 
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subsequent diagnostic conversions to BD or SZ. Individuals who convert may have different genetic 296 
profiles; however there was no way to account for this without conditioning on the future, which can 297 
introduce bias.
49
 Further research is needed to investigate the impact of polygenic liability on 298 
characteristics of course and outcome, including progression to other psychiatric disorders. Finally, the 299 
discovery datasets used to create the polygenic risk scores for MD, BD and SZ had different sample 300 
sizes, which impacts their statistical power.
50
  301 
Conclusions 302 
In conclusion, we found that polygenic liability predicts depression in the general Danish population. 303 
Polygenic liabilities for BD and SZ also predicted depression, which supports the idea that there is a 304 
shared genetic predisposition across these disorders. Heterogeneity in age at onset might be partially 305 
attributable to underlying genetic differences among depression cases, but these effects appear 306 
minimal. 307 
  308 
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Table 1 998 
Sample characteristics 999 
 
Case status 
Non-case Case 
N % N % 
Sex 
10,115 51.15 4,743 32.05 Male 
Female 9,659 48.85 10,056 67.95 
Age at depression diagnosis 
19,774 100.00 - - Non-case 
10-15 years - - 2,965 20.04 
16-20 years - - 6,653 44.96 
21-25 years - - 3,981 26.90 
26-31 years - - 1,200 8.11 
ICD-10 severity specifier 
19,774 100.00 - - Non-case 
Mild - - 2,573 17.39 
Moderate - - 6,635 44.83 
Severe without psychotic symptoms - - 1,386 9.37 
Severe with psychotic symptoms - - 481 3.25 
Severity unspecified - - 3,724 25.16 
Treatment setting 
19,774 100.00 - - Non-case 
Outpatient - - 8,880 60.00 
Inpatient - - 2,269 15.33 
Emergency - - 3,650 24.66 
Total sample 19,774 100.00 14,799 100.00 
 1000 
  1001 
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Table 2 1002 
Associations between PRS-MD, PRS-BD and PRS-SZ and hazard of depression within different age at 1003 
onset and severity subgroups 1004 
 MD BD SZ 
 HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
Age at depression diagnosis 10-15 1.27 (1.22, 1.33) <.0001 1.08 (1.04, 1.12) 0.0002 1.17 (1.12, 1.22) <.0001 
 16-20 1.31 (1.27, 1.35) <.0001 1.04 (1.01, 1.07) 0.008 1.12 (1.09, 1.16) <.0001 
 21-25 1.32 (1.27, 1.38) <.0001 1.04 (1.00, 1.08) 0.05 1.08 (1.04, 1.13) 0.0001 
 26-31 1.24 (1.16, 1.32) <.0001 1.02 (0.95, 1.10) 0.55 1.12 (1.04, 1.19) 0.0018 
ICD-10 severity specifier Mild 1.31 (1.26, 1.37) <.0001 1.06 (1.02, 1.11) 0.005 1.09 (1.04, 1.14) 0.0002 
 Moderate 1.31 (1.27, 1.35) <.0001 1.03 (1.00, 1.06) 0.04 1.13 (1.10, 1.17) <.0001 
 Severe 1.24 (1.18, 1.32) <.0001 1.08 (1.02, 1.14) 0.009 1.11 (1.05, 1.18) 0.0004 
 Psychotic 1.33 (1.23, 1.45) <.0001 1.13 (1.03, 1.24) 0.01 1.20 (1.09, 1.32) <.0001 
 Unspecified 1.30 (1.25, 1.35) <.0001 1.04 (1.01, 1.08) 0.02 1.11 (1.07, 1.15) <.0001 
Treatment setting Emergency 1.34 (1.29, 1.39) <.0001 1.07 (1.03, 1.11) 0.001 1.14 (1.10, 1.18) <.0001 
 Inpatient 1.33 (1.27, 1.39) <.0001 1.06 (1.01, 1.11) 0.01 1.13 (1.08, 1.18) <.0001 
 Outpatient 1.28 (1.24, 1.32) <.0001 1.04 (1.01, 1.07) 0.008 1.11 (1.08, 1.14) <.0001 
 1005 
MD = major depression, BD = bipolar disorder, SZ = schizophrenia, HR = hazard ratio, 95% CI = 95% 1006 
confidence interval. 1007 
 1008 
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Table 3 1009 
Case-only analyses of the effects of PRS-MD, PRS-BD and PRS-SZ on age at onset and severity at first depression diagnosis 1010 
 MD BD SZ 
 β SE OR (95% CI) p β SE OR (95% CI) p β SE OR (95% CI) p 
Age at depression diagnosis  -0.05 0.02 . 0.04 -0.07 0.02 . 0.002 -0.05 0.02 . 0.04 
ICD-10 severity specifier Mild ----- reference category ----- 
 Moderate -0.00 0.02 1.00 (0.95,1.05) 0.99 -0.03 0.02 0.97 (0.93,1.02) 0.24 0.04 0.02 1.04 (0.99,1.09) 0.08 
 Severe -0.05 0.03 0.95 (0.89,1.01) 0.13 0.02 0.03 1.02 (0.95,1.08) 0.62 0.02 0.03 1.02 (0.95,1.09) 0.58 
 Psychotic 0.02 0.05 1.02 (0.92, 1.12) 0.71 0.06 0.05 1.06 (0.97, 1.17) 0.21 0.09 0.05 1.10 (1.00, 1.21) 0.06 
 Unspecified -0.01 0.03 0.99 (0.94, 1.04) 0.77 -0.02 0.03 0.98 (0.93, 1.03) 0.48 0.02 0.03 1.02 (0.97, 1.07) 0.51 
Treatment setting Outpatient ----- reference category ----- 
 Emergency 0.05 0.02 1.05 (1.01,1.09) 0.02 0.03 0.02 1.03 (0.99,1.07) 0.18 0.03 0.02 1.03 (0.99,1.07) 0.13 
 Inpatient 0.04 0.02 1.04 (0.99,1.09) 0.13 0.02 0.02 1.02 (0.98,1.07) 0.37 0.02 0.02 1.02 (0.97,1.07) 0.46 
 1011 
MD = major depression, BD = bipolar disorder, SZ = schizophrenia, OR = odds ratio, 95% CI = 95% confidence interval.1012 
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Figure 1 1013 
Title: Polygenic liability for MD, BD and SZ and hazard of depression in the iPSYCH2012 cohort 1014 
 1015 
Explanatory legend: Hazard of depression for each decile of polygenic liability relative to the bottom 1016 
decile (i.e. the bottom 10% of the polygenic liability in the Danish population). Bars represent 95% 1017 
confidence intervals. MD = major depressive disorder, BD = bipolar disorder, SZ = schizophrenia.  1018 
  1019 
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Figure 2 1020 
Title: Polygenic liability for MD, BD and SZ and hazard of depression by age and severity  1021 
Explanatory legend: (A) Hazard ratios per standard deviation (SD) increase in polygenic liabilities for 1022 
MD, BD and SZ for depression diagnosis within different age ranges. (B) Hazard ratios per SD 1023 
increase in polygenic liabilities for MD, BD and SZ for depression diagnosis with different ICD-10 1024 
severity specifications. (C) Hazard ratios per SD increase in polygenic liabilities for MD, BD and SZ 1025 
for depression diagnosis within different treatment settings. Bars represent 95% confidence intervals. 1026 
MD = major depressive disorder, BD = bipolar disorder, SZ = schizophrenia.  1027 
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